Novel insights into molecular and cellular aspects of delayed drug hypersensitivity reactions

References

• Batel Marques F, Penedones A, Mendes D, et al. A systematic review of observational studies evaluating costs of adverse drug reactions. Clinicoecon Outcomes Res. 2016;8:413–426. doi: 10.2147/CEOR.S115689
   PubMed Web of Science ®Google Scholar
• Bates DW, Levine DM, Salmasian H, et al. The safety of inpatient health care. N Engl J Med. 2023 Jan 12;388(2):142–153. doi: 10.1056/NEJMsa2206117
   PubMed Web of Science ®Google Scholar
• Bordet R, Gautier S, Le Louet H, et al. Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur J Clin Pharmacol. 2001, Mar;56(12):935–941. doi: 10.1007/s002280000260
   PubMed Web of Science ®Google Scholar
• Gautier S, Bachelet H, Bordet R, et al. The cost of adverse drug reactions. Expert Opin Pharmacother. 2003, Mar;4(3):319–326. doi: 10.1517/14656566.4.3.319
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Ostrov DA, Park BK. New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. J Allergy Clin Immunol. 2015, Aug;136(2):236–244. doi: 10.1016/j.jaci.2015.06.022
   PubMed Web of Science ®Google Scholar
• Seo B, Yang MS, Park SY, et al. Incidence and economic burden of adverse drug reactions in hospitalization: a prospective study in Korea. J Korean Med Sci. 2023 Feb 27;38(8):e56. doi: 10.3346/jkms.2023.38.e56
   PubMed Web of Science ®Google Scholar
• Abou-Taleb DAE, El-Sayed AM, Ghabesha AA, et al. Severe cutaneous adverse drug reactions: incidence, clinical patterns, causative drugs and modalities of treatment in Assiut University Hospital, Upper Egypt. Dermatol Ther. 2020, Nov;33(6):e14176. doi: 10.1111/dth.14176
   PubMed Web of Science ®Google Scholar
• Cameron HA, Ramsay LE. The lupus syndrome induced by hydralazine: a common complication with low dose treatment. Br Med J (Clin Res Ed). 1984 Aug 18;289(6442):410–2
   PubMed Web of Science ®Google Scholar
• Uetrecht J, Naisbitt DJ, Ma Q. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev. 2013, Apr;65(2):779–808. doi: 10.1124/pr.113.007450
   PubMed Web of Science ®Google Scholar
• Elzagallaai AA, Rieder MJ. In vitro testing for diagnosis of idiosyncratic adverse drug reactions: implications for pathophysiology. Br J Clin Pharmacol. 2015, Oct;80(4):889–900. doi: 10.1111/bcp.12505
   PubMed Web of Science ®Google Scholar
• Elzagallaai AA, Rieder MJ. Genetic markers of drug hypersensitivity in pediatrics: current state and promise. Expert Rev Clin Pharmacol. 2022 Jul 9;15(6):715–728. doi: 10.1080/17512433.2022.2100345
   PubMed Web of Science ®Google Scholar
• Alfirevic A, Pirmohamed M. Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future. Pharmacogenomics. 2010, Apr;11(4):497–499. doi: 10.2217/pgs.10.12
   PubMed Web of Science ®Google Scholar
• Kuruvilla R, Scott K, Pirmohamed SM. Pharmacogenomics of drug hypersensitivity: technology and translation. Immunol Allergy Clin North Am. 2022, May;42(2):335–355. doi: 10.1016/j.iac.2022.01.006
   PubMed Web of Science ®Google Scholar
• Sukasem C, Puangpetch A, Medhasi S, et al. Pharmacogenomics of drug-induced hypersensitivity reactions: challenges, opportunities and clinical implementation. Asian Pac J Allergy Immunol. 2014 Jun;32(2):111–123.
   PubMed Web of Science ®Google Scholar
• Turner RM, Magavern EF, Pirmohamed M. Pharmacogenomics: relevance and opportunities for clinical pharmacology. Br J Clin Pharmacol. 2022 Mar 28;88(9):3943–3946. doi: 10.1111/bcp.15329
   PubMed Web of Science ®Google Scholar
• Johansson SG, Hourihane JO, Bousquet J, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force [guideline review]. Allergy. 2001, Sep;56(9):813–24. doi: 10.1111/j.1398-9995.2001.00002.x-i1
   PubMed Web of Science ®Google Scholar
• Brockow K, Wurpts G, Trautmann A, et al. Guideline for allergological diagnosis of drug hypersensitivity reactions: S2k guideline of the German Society for Allergology and clinical immunology (DGAKI) in cooperation with the German dermatological Society (DDG), the Association of German Allergologists (ADA), the German Society for Pediatric Allergology (GPA), the German contact Dermatitis research group (DKG), the German Society for pneumology (DGP), the German Society of Otorhinolaryngology, head and neck surgery, the Austrian Society of Allergology and immunology (OGAI), the Austrian Society of Dermatology and venereology (OGDV), the German academy of Allergology and Environmental Medicine (DAAU), and the German documentation center for severe skin reactions (dZh). Allergol Select. 2023;7:122–139. doi: 10.5414/ALX02422E
   PubMedGoogle Scholar
• Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: report of the nomenclature review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004, May;113(5):832–6. doi: 10.1016/j.jaci.2003.12.591
   PubMed Web of Science ®Google Scholar
• Demoly P, Viola M, Rebelo Gomes E, et al. Epidemiology and causes of drug hypersensitivity. In: Pichler Weditor. Drug hypersensitivity. Basel: Karger; 2007. p. 2–17.
   Google Scholar
• Pagani S, Lombardi N, Crescioli G, et al. Drug-related hypersensitivity reactions leading to emergency department: original data and systematic review. J Clin Med. 2022 May 16;11(10):2811. doi: 10.3390/jcm11102811
   PubMed Web of Science ®Google Scholar
• Coombs R, Gell P. Classifications of allergi reactions responsible for clinical hypersensitivity and disease. In: Gell P, Coombs R Lachman P, editors Clinical aspects of immunology. London: Blackwell Scientific Publications; 1975. p. 761–81.
   Google Scholar
• Gell PG, Coombs RR. Clinical aspects of immunology. Clin Aspects Immunol. 1963;xxvi–883.
   Google Scholar
• Pichler WJ. Immune pathomechanism and classification of drug hypersensitivity. Allergy. 2019, Aug;74(8):1457–1471. doi: 10.1111/all.13765
   PubMed Web of Science ®Google Scholar
• Pichler WJ, Adam J, Daubner B, et al. Drug hypersensitivity reactions: pathomechanism and clinical symptoms. Med Clin North Am. 2010, Jul;94(4):645–664, xv. doi: 10.1016/j.mcna.2010.04.003
   PubMed Web of Science ®Google Scholar
• Demoly P, Adkinson NF, Brockow K, et al. International consensus on drug allergy. Allergy. 2014, Apr;69(4):420–437. doi: 10.1111/all.12350
   PubMed Web of Science ®Google Scholar
• Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003 Oct 21;139(8):683–693. doi: 10.7326/0003-4819-139-8-200310210-00012
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Chem Immunol Allergy. 2012;97:1–17.
   PubMedGoogle Scholar
• Wang CW, Divito SJ, Chung WH, et al. Advances in the pathomechanisms of delayed drug hypersensitivity. Immunol Allergy Clin North Am. 2022, May;42(2):357–373. doi: 10.1016/j.iac.2022.01.002
   PubMed Web of Science ®Google Scholar
• Likic R, Bevanda Glibo D. Pathophysiology of allergic drug reactions. Psychiatr Danub. 2019 Mar;31(Suppl 1):66–69.
   PubMedGoogle Scholar
• Balakirski G, Merk HF. Cutaneous allergic drug reactions: update on pathophysiology, diagnostic procedures and differential diagnosic. Cutan Ocul Toxicol. 2017, Dec;36(4):307–316. doi: 10.1080/15569527.2017.1319379
   PubMed Web of Science ®Google Scholar
• Armitage KF, Porter CE, Ahmed S, et al. Penicillin allergy status and its effect on antibiotic prescribing, patient outcomes and antimicrobial resistance (ALABAMA): protocol for a multicentre, parallel-arm, open-label, randomised pragmatic trial. BMJ Open. 2023 Sep 4;13(9):e072253. doi: 10.1136/bmjopen-2023-072253
   PubMedGoogle Scholar
• Rodriguez-Perez R, de Las Vecillas L, Cabanas R, et al. Tools for etiologic diagnosis of drug-induced allergic conditions. Int J Mol Sci. 2023 Aug 8;24(16):12577. doi: 10.3390/ijms241612577
   PubMed Web of Science ®Google Scholar
• Sibbald C, Shear NH, Verstegen RHJ. Flaws and limitations of classification criteria for drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol Pract. 2023, Sep;11(9):2693–2696. doi: 10.1016/j.jaip.2023.05.017
   PubMed Web of Science ®Google Scholar
• Benahmed S, Picot MC, Dumas F, et al. Accuracy of a pharmacovigilance algorithm in diagnosing drug hypersensitivity reactions. Arch Intern Med. 2005 Jul 11;165(13):1500–1505. doi: 10.1001/archinte.165.13.1500
   PubMedGoogle Scholar
• Um SH, Abuzgaia A, Rieder M. Comparison of the liverpool causality assessment tool vs. the naranjo scale for predicting the likelihood of an adverse drug reaction: a retrospective cohort study. Br J Clin Pharmacol. 2023, Aug;89(8):2407–2412. doi: 10.1111/bcp.15704
   PubMed Web of Science ®Google Scholar
• Benahmed S, Picot MC, Hillaire-Buys D, et al. Comparison of pharmacovigilance algorithms in drug hypersensitivity reactions. Eur J Clin Pharmacol. 2005, Aug;61(7):537–541. doi: 10.1007/s00228-005-0962-1
   PubMed Web of Science ®Google Scholar
• Elzagallaai AA, Jahedmotlagh Z, Del Pozzo-Magana BR, et al. Predictive value of the lymphocyte toxicity assay in the diagnosis of drug hypersensitivity syndrome. Mol Diagn Ther. 2010 Oct 1;14(5):317–322. doi: 10.1007/BF03256387
   PubMed Web of Science ®Google Scholar
• Elzagallaai AA, Knowles SR, Rieder MJ, et al. In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Mol Diagn Ther. 2009;13(5):313–330.
   PubMed Web of Science ®Google Scholar
• Elzagallaai AA, Koren G, Bend JR, et al. In vitro testing for hypersensitivity-mediated adverse drug reactions: challenges and future directions. Clin Pharmacol Ther. 2011, Sep;90(3):455–460. doi: 10.1038/clpt.2011.155
   PubMed Web of Science ®Google Scholar
• Elzagallaai AA, Koren G, Rieder MJ. The predictive value of the in vitro platelet toxicity assay (iPTA) for the diagnosis of hypersensitivity reactions to sulfonamides. J Clin Pharmacol. 2013, Jun;53(6):626–632. doi: 10.1002/jcph.85
   PubMed Web of Science ®Google Scholar
• Elzagallaai AA, Rieder MJ, Koren G. The in vitro platelet toxicity assay (iPTA): a novel approach for assessment of drug hypersensitivity syndrome. J Clin Pharmacol. 2011, Mar;51(3):428–435. doi: 10.1177/0091270010365554
   PubMed Web of Science ®Google Scholar
• Chiriac AM, Demoly P. Drug provocation tests: up-date and novel approaches. Allergy, Asthma Clin Immunol. 2013 Apr 3;9(1):12. doi: 10.1186/1710-1492-9-12
   PubMedGoogle Scholar
• Moral L, Mori F. Drug provocation tests in children: all that glitters is not gold. Pediatr Allergy Immunol. 2023, Aug;34(8):e14002. doi: 10.1111/pai.14002
   PubMed Web of Science ®Google Scholar
• Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005 Apr 15;209(2):123–129. doi: 10.1016/j.tox.2004.12.022
   PubMed Web of Science ®Google Scholar
• Bigby M. Incidence, prevalence and the rates of cutaneous reactions to drugs. J Eur Acad Dermatol Venereol. 2000, Nov;14(6):435. doi: 10.1046/j.1468-3083.2000.00167.x
   PubMed Web of Science ®Google Scholar
• Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001, Jun;137(6):765–70. doi: 10.1001/archderm.137.12.1639
   PubMed Web of Science ®Google Scholar
• Crowson AN, Brown TJ, Magro CM. Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions: implications for management. Am J Clin Dermatol. 2003;4(6):407–428. doi: 10.2165/00128071-200304060-00005
   PubMed Web of Science ®Google Scholar
• Duong TA, Valeyrie-Allanore L, Wolkenstein P, et al. Severe cutaneous adverse reactions to drugs. Lancet. 2017 Oct 28;390(10106):1996–2011. doi: 10.1016/S0140-6736(16)30378-6
   PubMed Web of Science ®Google Scholar
• Cekic S, Canitez Y, Yuksel H, et al. A comprehensive assessment of long-term complications in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Int Arch Allergy Immunol. 2023 Jul 26;184(10):994–1002. doi: 10.1159/000531366
   PubMed Web of Science ®Google Scholar
• Hama N, Sunaga Y, Ochiai H, et al. Development and validation of a novel score to predict mortality in Stevens-Johnson syndrome and toxic epidermal necrolysis: CRISTEN. J Allergy Clin Immunol Pract. 2023 Jul 8;11(10):3161–3168.e2. doi: 10.1016/j.jaip.2023.07.001
   PubMed Web of Science ®Google Scholar
• Saito Y, Abe R. New insights into the diagnosis and management of Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Opin Allergy Clin Immunol. 2023 Aug 1;23(4):271–278. doi: 10.1097/ACI.0000000000000914
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M. The current understanding of Stevens–Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011, Nov;7(6):803–815. doi: 10.1586/eci.11.66
   PubMed Web of Science ®Google Scholar
• Hosack T, Damry D, Biswas S. Drug-induced liver injury: a comprehensive review. Therap Adv Gastroenterol. 2023;16:17562848231163410. doi: 10.1177/17562848231163410
   Web of Science ®Google Scholar
• Teschke R, Uetrecht J. Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues. Ann Transl Med. 2021, Apr;9(8):730. doi: 10.21037/atm-2020-ubih-05
   PubMed Web of Science ®Google Scholar
• Jee A, Sernoskie SC, Uetrecht J. Idiosyncratic drug-induced liver injury: mechanistic and clinical challenges. Int J Mol Sci. 2021 Mar 14;22(6):2954. doi: 10.3390/ijms22062954
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Robles M, Ulzurrun E, et al. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics. 2009, Sep;10(9):1467–1487. doi: 10.2217/pgs.09.111
   PubMed Web of Science ®Google Scholar
• Martinez-Cabriales SA, Rodriguez-Bolanos F, Shear NH. Drug reaction with Eosinophilia and systemic symptoms (DReSS): how far have we come? Am J Clin Dermatol. 2019, Apr;20(2):217–236. doi: 10.1007/s40257-018-00416-4
   PubMed Web of Science ®Google Scholar
• Hama N, Abe R, Gibson A, et al. Drug-induced hypersensitivity syndrome (Dihs)/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis. J Allergy Clin Immunol Pract. 2022, May;10(5):1155–1167 e5. doi: 10.1016/j.jaip.2022.02.004
   PubMed Web of Science ®Google Scholar
• Thongsri T, Chularojanamontri L, Pichler WJ. Cardiac involvement in DRESS syndrome. Asian Pac J Allergy Immunol. 2017, Mar;35(1):3–10. doi: 10.12932/AP0847
   PubMed Web of Science ®Google Scholar
• Shiohara T, Kano Y. Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management. Expert Opin Drug Saf. 2017, Feb;16(2):139–147. doi: 10.1080/14740338.2017.1270940
   PubMed Web of Science ®Google Scholar
• Shiohara T, Iijima M, Ikezawa Z, et al. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol. 2007, May;156(5):1083–1084. doi: 10.1111/j.1365-2133.2007.07807.x
   PubMed Web of Science ®Google Scholar
• Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple chemical compounds. J Exp Med. 1935 Apr 30;61(5):643–656. doi: 10.1084/jem.61.5.643
   PubMedGoogle Scholar
• Park BK, Kitteringham NR, Powell H, et al. Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. Toxicology. 2000 Nov 16;153(1–3):39–60. doi: 10.1016/S0300-483X(00)00303-6
   PubMed Web of Science ®Google Scholar
• Blumberg PM, Strominger JL. Interaction of penicillin with the bacterial cell: penicillin-binding proteins and penicillin-sensitive enzymes. Bacteriol Rev. 1974, Sep;38(3):291–335. doi: 10.1128/br.38.3.291-335.1974
   PubMedGoogle Scholar
• Lima LM, Silva B, Barbosa G, et al. Beta-lactam antibiotics: an overview from a medicinal chemistry perspective. Eur J Med Chem. 2020 Dec 15;208:112829. doi: 10.1016/j.ejmech.2020.112829
   PubMed Web of Science ®Google Scholar
• Zdziarski P. Electrophoretic properties of beta-lactam and serum protein conjugates. Acta Pol Pharm. 2000 Nov;57(6):411–413.
   PubMedGoogle Scholar
• Meng X, Al-Attar Z, Yaseen FS, et al. Definition of the nature and hapten threshold of the beta-lactam antigen required for T cell activation in vitro and in patients. J Immunol. 2017 Jun 1;198(11):4217–4227. doi: 10.4049/jimmunol.1700209
   PubMed Web of Science ®Google Scholar
• Bechara R, Maillere B, Joseph D, et al. Identification and characterization of a naive CD8+ T cell repertoire for benzylpenicillin. Clin Exp Allergy. 2019, May;49(5):636–643. doi: 10.1111/cea.13338
   PubMed Web of Science ®Google Scholar
• Padovan E, Mauri-Hellweg D, Pichler WJ, et al. T cell recognition of penicillin G: structural features determining antigenic specificity. Eur J Immunol. 1996, Jan;26(1):42–48. doi: 10.1002/eji.1830260107
   PubMed Web of Science ®Google Scholar
• Brander C, Mauri-Hellweg D, Bettens F, et al. Heterogeneous T cell responses to beta-lactam-modified self-structures are observed in penicillin-allergic individuals. J Immunol. 1995 Sep 1;155(5):2670–2678. doi: 10.4049/jimmunol.155.5.2670
   PubMed Web of Science ®Google Scholar
• Nicoletti P, Aithal GP, Chamberlain TC, et al. Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. Clin Pharmacol Ther. 2019, Jul;106(1):245–253. doi: 10.1002/cpt.1375
   PubMed Web of Science ®Google Scholar
• Manson LEN, Swen JJ, Guchelaar HJ. Diagnostic test criteria for HLA genotyping to prevent drug hypersensitivity reactions: a systematic review of actionable HLA recommendations in CPIC and DPWG guidelines. Front Pharmacol. 2020;11:567048. doi: 10.3389/fphar.2020.567048
   PubMed Web of Science ®Google Scholar
• Gao Y, Song B, Aoki S, et al. Conjugation of human serum albumin and flucloxacillin provokes specific immune response in HLA-B*57:01 transgenic mice. Immunol Lett. 2022, Sep;249:5–11
   PubMed Web of Science ®Google Scholar
• Pallardy M, Bechara R. Chemical or drug hypersensitivity: is the immune system clearing the danger? Toxicol Sci. 2017 Jul 1;158(1):14–22. doi: 10.1093/toxsci/kfx084
   PubMed Web of Science ®Google Scholar
• Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol. 2001, Feb;13(1):114–9. doi: 10.1016/S0952-7915(00)00191-6
   PubMed Web of Science ®Google Scholar
• Mitchell JR, Jollow DJ, Potter WZ, et al. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther. 1973 Oct;187(1):185–194.
   PubMed Web of Science ®Google Scholar
• Boyd MR, Burka LT, Wilson BJ. Distribution, excretion, and binding of radioactivity in the rat after intraperitoneal administration of the lung-toxic furan, [14C]4-ipomeanol. Toxicol Appl Pharmacol. 1975, Apr;32(1):147–57. doi: 10.1016/0041-008X(75)90205-7
   PubMed Web of Science ®Google Scholar
• Gillette JR, Michell JR, Brodie BB. Biochemical mechanisms of drug toxicity. Ann Rev Pharmacol. 1974;14:271–288. doi: 10.1146/annurev.pa.14.040174.001415
   Google Scholar
• Jollow DJ, Mitchell JR, Potter WZ, et al. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther. 1973 Oct;187(1):195–202.
   PubMed Web of Science ®Google Scholar
• Reid WD, Krishna G, Gillette R, et al. Biochemical mechanism of hepatic necrosis induced by aromatic hydrocarbons. Pharmacology. 1973;10(4):193–214.
   PubMed Web of Science ®Google Scholar
• Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med. 1976, Feb;84(2):181–92. doi: 10.7326/0003-4819-84-2-181
   PubMed Web of Science ®Google Scholar
• Park BK, Naisbitt DJ, Gordon SF, et al. Metabolic activation in drug allergies. Toxicology. 2001 Feb 2;158(1–2):11–23. doi: 10.1016/S0300-483X(00)00397-8
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Kitteringham NR, Park BK. The role of active metabolites in drug toxicity. Drug Saf. 1994, Aug;11(2):114–144. doi: 10.2165/00002018-199411020-00006
   PubMed Web of Science ®Google Scholar
• Naisbitt DJ, Williams DP, Pirmohamed M, et al. Reactive metabolites and their role in drug reactions. Curr Opin Allergy Clin Immunol. 2001, Aug;1(4):317–325. doi: 10.1097/00130832-200108000-00007
   PubMed Web of Science ®Google Scholar
• Elzagallaai AA, Sultan EA, Bend JR, et al. Role of oxidative stress in hypersensitivity reactions to sulfonamides. J Clin Pharmacol. 2020, Mar;60(3):409–421. doi: 10.1002/jcph.1535
   PubMed Web of Science ®Google Scholar
• Ali SE, Meng X, Kafu L, et al. Detection of hepatic drug metabolite-specific T-Cell responses using a human hepatocyte, immune cell coculture system. Chem Res Toxicol. 2023 Mar 20;36(3):390–401. doi: 10.1021/acs.chemrestox.2c00343
   PubMed Web of Science ®Google Scholar
• Ju C, Uetrecht JP. Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. J Pharmacol Exp Ther. 1999 Jan;288(1):51–56.
   PubMed Web of Science ®Google Scholar
• Kato R, Ijiri Y, Hayashi T, et al. The 2-hydroxyiminostilbene metabolite of carbamazepine or the supernatant from incubation of hepatocytes with carbamazepine activates inflammasomes: implications for carbamazepine-induced hypersensitivity reactions. Drug Metab Dispos. 2019, Oct;47(10):1093–1096. doi: 10.1124/dmd.119.087981
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Kitteringham NR, Guenthner TM, et al. An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochem Pharmacol. 1992 Apr 15;43(8):1675–1682. doi: 10.1016/0006-2952(92)90696-G
   PubMed Web of Science ®Google Scholar
• Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet. 2000 Nov 4;356(9241):1587–1591. doi: 10.1016/S0140-6736(00)03137-8
   PubMed Web of Science ®Google Scholar
• Szultka M, Krzeminski R, Jackowski M, et al. Identification of in vitro metabolites of amoxicillin in human liver microsomes by LC-ESI/MS. Chromatographia. 2014;77:1027–1035. doi: 10.1007/s10337-014-2648-2
   PubMed Web of Science ®Google Scholar
• Born SL, Hu JK, Lehman-McKeeman LD. O-hydroxyphenylacetaldehyde is a hepatotoxic metabolite of coumarin. Drug Metab Dispos. 2000 Feb;28(2):218–223.
   PubMed Web of Science ®Google Scholar
• Sharma AM, Klarskov K, Uetrecht J. Nevirapine bioactivation and covalent binding in the skin. Chem Res Toxicol. 2013 Mar 18;26(3):410–421. doi: 10.1021/tx3004938
   PubMed Web of Science ®Google Scholar
• Sharma AM, Novalen M, Tanino T, et al. 12-OH-nevirapine sulfate, formed in the skin, is responsible for nevirapine-induced skin rash. Chem Res Toxicol. 2013 May 20;26(5):817–827. doi: 10.1021/tx400098z
   PubMed Web of Science ®Google Scholar
• Uetrecht J. Idiosyncratic drug reactions: a 35-year chemical research in Toxicology perspective. Chem Res Toxicol. 2022 Jun 10;35(10):1649–1654. doi: 10.1021/acs.chemrestox.2c00090
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12(1):991–1045. doi: 10.1146/annurev.iy.12.040194.005015
   PubMedGoogle Scholar
• Zhao T, Cai Y, Jiang Y, et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct Target Ther. 2023 Jul 19;8(1):283. doi: 10.1038/s41392-023-01557-7
   PubMed Web of Science ®Google Scholar
• Matzinger P. An innate sense of danger. Semin Immunol. 1998, Oct;10(5):399–415. doi: 10.1006/smim.1998.0143
   PubMed Web of Science ®Google Scholar
• Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the “danger hypothesis” and innate immune system. Chem Res Toxicol. 1999, May;12(5):387–395. doi: 10.1021/tx980249i
   PubMed Web of Science ®Google Scholar
• Zhang X, Sharma AM, Uetrecht J. Identification of danger signals in nevirapine-induced skin rash. Chem Res Toxicol. 2013 Sep 16;26(9):1378–1383. doi: 10.1021/tx400232s
   PubMed Web of Science ®Google Scholar
• Bergmann C, Poli A, Agache I, et al. AllergoOncology: danger signals in allergology and oncology: a European Academy of Allergy and clinical immunology (EAACI) position paper. Allergy. 2022 Feb 13;77(9):2594–2617. doi: 10.1111/all.15255
   PubMed Web of Science ®Google Scholar
• Sanchez-Quintero MJ, Torres MJ, Blazquez AB, et al. Synergistic effect between amoxicillin and TLR ligands on dendritic cells from amoxicillin-delayed allergic patients. PLoS One. 2013;8(9):e74198.
   PubMed Web of Science ®Google Scholar
• Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med. 1999, Nov;5(11):1249–1255. doi: 10.1038/15200
   PubMed Web of Science ®Google Scholar
• Ramirez GA, Ripa M, Burastero S, et al. Drug reaction with Eosinophilia and systemic symptoms (DRESS): focus on the pathophysiological and diagnostic role of viruses. Microorganisms. 2023 Jan 30;11(2). doi: 10.3390/microorganisms11020346
   Web of Science ®Google Scholar
• Shiohara T, Ushigome Y, Kano Y, et al. Crucial role of viral reactivation in the development of severe drug eruptions: a comprehensive review. Clin Rev Allergy Immunol. 2015, Oct;49(2):192–202. doi: 10.1007/s12016-014-8421-3
   PubMed Web of Science ®Google Scholar
• Levy M. The combined effect of viruses and drugs in drug-induced diseases. Med Hypotheses. 1984, Jul;14(3):293–296. doi: 10.1016/0306-9877(87)90131-9
   PubMed Web of Science ®Google Scholar
• Onodi-Nagy K, Kinyo A, Meszes A, et al. Amoxicillin rash in patients with infectious mononucleosis: evidence of true drug sensitization. Allergy, Asthma Clin Immunol. 2015;11(1):1.
   PubMedGoogle Scholar
• Renn CN, Straff W, Dorfmuller A, et al. Amoxicillin-induced exanthema in young adults with infectious mononucleosis: demonstration of drug-specific lymphocyte reactivity. Br J Dermatol. 2002, Dec;147(6):1166–1170. doi: 10.1046/j.1365-2133.2002.05021.x
   PubMed Web of Science ®Google Scholar
• Thompson DF, Ramos CL. Antibiotic-induced rash in patients with infectious mononucleosis. Ann Pharmacother. 2017, Feb;51(2):154–162. doi: 10.1177/1060028016669525
   PubMed Web of Science ®Google Scholar
• Shiohara T, Kano Y. A complex interaction between drug allergy and viral infection. Clin Rev Allergy Immunol. 2007, Oct;33(1–2):124–133. doi: 10.1007/s12016-007-8010-9
   PubMed Web of Science ®Google Scholar
• Coopman SA, Johnson RA, Platt R, et al. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993 Jun 10;328(23):1670–1674. doi: 10.1056/NEJM199306103282304
   PubMed Web of Science ®Google Scholar
• Rzany B, Mockenhaupt M, Stocker U, et al. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch Dermatol. 1993, Aug;129(8):1059. doi: 10.1001/archderm.1993.01680290135026
   PubMedGoogle Scholar
• Chimbetete T, Buck C, Choshi P, et al. HIV-Associated immune dysregulation in the skin: a crucible for exaggerated inflammation and hypersensitivity. J Invest Dermatol. 2023, Mar;143(3):362–373. doi: 10.1016/j.jid.2022.07.035
   PubMed Web of Science ®Google Scholar
• Adeyanju K, Bend JR, Rieder MJ, et al. HIV-1 tat expression and sulphamethoxazole hydroxylamine mediated oxidative stress alter the disulfide proteome in jurkat T cells. Virol J. 2018 May 9;15(1):82. doi: 10.1186/s12985-018-0991-x
   PubMedGoogle Scholar
• Bigby M, Jick S, Jick H, et al. Drug-induced cutaneous reactions. A report from the Boston collaborative drug surveillance program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986 Dec 26;256(24):3358–63. doi: 10.1001/jama.1986.03380240052027
   PubMed Web of Science ®Google Scholar
• Gordin FM, Simon GL, Wofsy CB, et al. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1984, Apr;100(4):495–9. doi: 10.7326/0003-4819-100-4-495
   PubMed Web of Science ®Google Scholar
• Hennessy S, Strom BL, Berlin JA, et al. Predicting cutaneous hypersensitivity reactions to cotrimoxazole in HIV-infected individuals receiving primary Pneumocystis carinii pneumonia prophylaxis. J Gen Intern Med. 1995, Jul;10(7):380–386. doi: 10.1007/BF02599836
   PubMed Web of Science ®Google Scholar
• Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med. 1990 Sep 20;323(12):776–782. doi: 10.1056/NEJM199009203231202
   PubMed Web of Science ®Google Scholar
• Walmsley SL, Khorasheh S, Singer J, et al. A randomized trial of N-acetylcysteine for prevention of trimethoprim-sulfamethoxazole hypersensitivity reactions in Pneumocystis carinii pneumonia prophylaxis (CTN 057). Canadian HIV trials network 057 study group. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 15;19(5):498–505. doi: 10.1097/00042560-199812150-00009
   PubMedGoogle Scholar
• Picard D, Janela B, Descamps V, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med. 2010 Aug 25;2(46):46ra62. doi: 10.1126/scitranslmed.3001116
   PubMed Web of Science ®Google Scholar
• Almeida CA, van Miert P, O’Driscoll K, et al. Virus-specific T-cell clonotypes might contribute to drug hypersensitivity reactions through heterologous immunity. J Allergy Clin Immunol. 2019, Aug;144(2):608–611 e4. doi: 10.1016/j.jaci.2019.05.009
   PubMed Web of Science ®Google Scholar
• Pavlos R, Mallal S, Ostrov D, et al. Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy. J Allergy Clin Immunol Pract. 2014, Jan;2(1):21–33. doi: 10.1016/j.jaip.2013.11.005
   PubMed Web of Science ®Google Scholar
• Asano Y, Kagawa H, Kano Y, et al. Cytomegalovirus disease during severe drug eruptions: report of 2 cases and retrospective study of 18 patients with drug-induced hypersensitivity syndrome. Arch Dermatol. 2009, Sep;145(9):1030–1036. doi: 10.1001/archdermatol.2009.195
   PubMed Web of Science ®Google Scholar
• Aota N, Shiohara T. Viral connection between drug rashes and autoimmune diseases: how autoimmune responses are generated after resolution of drug rashes. Autoimmun Rev. 2009, May;8(6):488–494. doi: 10.1016/j.autrev.2009.02.029
   PubMed Web of Science ®Google Scholar
• Tohyama M, Hashimoto K, Yasukawa M, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol. 2007, Nov;157(5):934–940. doi: 10.1111/j.1365-2133.2007.08167.x
   PubMed Web of Science ®Google Scholar
• Seishima M, Yamanaka S, Fujisawa T, et al. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol. 2006, Aug;155(2):344–349. doi: 10.1111/j.1365-2133.2006.07332.x
   PubMed Web of Science ®Google Scholar
• Kano Y, Hiraharas K, Sakuma K, et al. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol. 2006, Aug;155(2):301–306. doi: 10.1111/j.1365-2133.2006.07238.x
   PubMed Web of Science ®Google Scholar
• Shiohara T, Kano Y. Are viral infections responsible for the development of drug-induced hypersensitivity syndrome as well as graft-versus-host diseases? Dermatology. 2005;210(4):259–260. doi: 10.1159/000084747
   PubMed Web of Science ®Google Scholar
• Kano Y, Inaoka M, Shiohara T. Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch Dermatol. 2004, Feb;140(2):183–188. doi: 10.1001/archderm.140.2.183
   PubMedGoogle Scholar
• Descamps V, Valance A, Edlinger C, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol. 2001 Mar;137(3):301–304.
   PubMedGoogle Scholar
• Tohyama M, Yahata Y, Yasukawa M, et al. Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. Arch Dermatol. 1998, Sep;134(9):1113–1117. doi: 10.1001/archderm.134.9.1113
   PubMedGoogle Scholar
• Suzuki Y, Inagi R, Aono T, et al. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol. 1998, Sep;134(9):1108–1112. doi: 10.1001/archderm.134.9.1108
   PubMedGoogle Scholar
• Pichler WJ, Bruggen MC. Viral infections and drug hypersensitivity. Allergy. 2023 Jan;78(1):60–70. doi: 10.1111/all.15558
   PubMed Web of Science ®Google Scholar
• Miyagawa F, Asada H. Current perspective regarding the Immunopathogenesis of drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS). Int J Mol Sci. 2021 Feb 21;22(4):2147. doi: 10.3390/ijms22042147
   PubMed Web of Science ®Google Scholar
• Shiohara T. Viral infections, allergy and autoimmunity: a complex, but fascinating link. Journal Of Dermatological Science. 2000 Apr;22(3):149–51. doi: 10.1016/S0923-1811(99)00080-8
   PubMed Web of Science ®Google Scholar
• Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int. 2006, Mar;55(1):1–8. doi: 10.2332/allergolint.55.1
   PubMedGoogle Scholar
• Elzagallaai AA, Rieder MJ. Pathophysiology of drug hypersensitivity. Br J Clin Pharmacol. 2022 Dec 14. doi: 10.1111/bcp.15645
   Web of Science ®Google Scholar
• Selin LK, Brehm MA, Naumov YN, et al. Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity. Immunol Rev. 2006, Jun;211(1):164–181. doi: 10.1111/j.0105-2896.2006.00394.x
   PubMedGoogle Scholar
• Selin LK, Cornberg M, Brehm MA, et al. CD8 memory T cells: cross-reactivity and heterologous immunity. Semin Immunol. 2004, Oct;16(5):335–347. doi: 10.1016/j.smim.2004.08.014
   PubMed Web of Science ®Google Scholar
• Welsh RM, Che JW, Brehm MA, et al. Heterologous immunity between viruses. Immunol Rev. 2010, May;235(1):244–266. doi: 10.1111/j.0105-2896.2010.00897.x
   PubMed Web of Science ®Google Scholar
• Shen ZT, Nguyen TT, Daniels KA, et al. Disparate epitopes mediating protective heterologous immunity to unrelated viruses share peptide-MHC structural features recognized by cross-reactive T cells. J Immunol. 2013 Nov 15;191(10):5139–52. doi: 10.4049/jimmunol.1300852
   PubMed Web of Science ®Google Scholar
• Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today. 1998, Sep;19(9):395–404. doi: 10.1016/S0167-5699(98)01299-7
   PubMedGoogle Scholar
• Macdonald WA, Chen Z, Gras S, et al. T cell allorecognition via molecular mimicry. Immunity. 2009 Dec 18;31(6):897–908. doi: 10.1016/j.immuni.2009.09.025
   PubMed Web of Science ®Google Scholar
• Abuzgaia AM, Elzagallaai AA, Mullowney T, et al. Drug hypersensitivity reactions in patients with cystic fibrosis: potential value of the lymphocyte toxicity assay to assess risk. Mol Diagn Ther. 2023 Mar 20;27(3):395–403. doi: 10.1007/s40291-023-00644-3
   PubMedGoogle Scholar
• Mazza C, Auphan-Anezin N, Gregoire C, et al. How much can a T-cell antigen receptor adapt to structurally distinct antigenic peptides? EMBO J. 2007 Apr 4;26(7):1972–1983. doi: 10.1038/sj.emboj.7601605
   PubMed Web of Science ®Google Scholar
• Yin Y, Mariuzza RA. The multiple mechanisms of T cell receptor cross-reactivity. Immunity. 2009 Dec 18;31(6):849–851. doi: 10.1016/j.immuni.2009.12.002
   PubMed Web of Science ®Google Scholar
• Yerly D, Pompeu YA, Schutte RJ, et al. Structural elements recognized by Abacavir-Induced T Cells. Int J Mol Sci. 2017 Jul 7;18(7):1464. doi: 10.3390/ijms18071464
   PubMed Web of Science ®Google Scholar
• Gorovits B, Clements-Egan A, Birchler M, et al. Pre-existing antibody: biotherapeutic modality-based review. AAPS J. 2016, Mar;18(2):311–320. doi: 10.1208/s12248-016-9878-1
   PubMed Web of Science ®Google Scholar
• Baldo BA, Fisher MM, Pham NH. On the origin and specificity of antibodies to neuromuscular blocking (muscle relaxant) drugs: an immunochemical perspective. Clin Exp Allergy. 2009, Mar;39(3):325–344. doi: 10.1111/j.1365-2222.2008.03171.x
   PubMed Web of Science ®Google Scholar
• Schnyder B, Mauri-Hellweg D, Zanni M, et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest. 1997 Jul 1;100(1):136–141. doi: 10.1172/JCI119505
   PubMed Web of Science ®Google Scholar
• Moulon C, Vollmer J, Weltzien HU. Characterization of processing requirements and metal cross-reactivities in T cell clones from patients with allergic contact dermatitis to nickel. Eur J Immunol. 1995, Dec;25(12):3308–3315. doi: 10.1002/eji.1830251216
   PubMed Web of Science ®Google Scholar
• Romagnoli P, Spinas GA, Sinigaglia F. Gold-specific T cells in rheumatoid arthritis patients treated with gold. J Clin Invest. 1992, Jan;89(1):254–258. doi: 10.1172/JCI115569
   PubMed Web of Science ®Google Scholar
• Pichler WJ. The important role of non-covalent drug-protein interactions in drug hypersensitivity reactions. Allergy. 2022, Feb;77(2):404–415. doi: 10.1111/all.14962
   PubMed Web of Science ®Google Scholar
• Pichler WJ, Beeler A, Keller M, et al. Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol Int. 2006, Mar;55(1):17–25. doi: 10.2332/allergolint.55.17
   PubMedGoogle Scholar
• Pichler WJ. The p-i concept: pharmacological interaction of drugs with immune receptors. World Allergy Organ J. 2008, Jun;1(6):96–102. doi: 10.1097/WOX.0b013e3181778282
   PubMedGoogle Scholar
• Andrade RJ, Aithal GP, de Boer YS, et al. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): an expert opinion meeting report. J Hepatol. 2023 May 8;79(3):853–866. doi: 10.1016/j.jhep.2023.04.033
   PubMed Web of Science ®Google Scholar
• Pichler WJ, Thoo L, Yerly D. Drug hypersensitivity and eosinophilia: the decisive role of p-i stimulation. Allergy. 2023 Jul 3;78(10):2596–2605. doi: 10.1111/all.15795
   PubMedGoogle Scholar
• Pichler WJ, Watkins S, Yerly D. Risk assessment in drug hypersensitivity: detecting small molecules which outsmart the immune system. Front Allergy. 2022;3:827893. doi: 10.3389/falgy.2022.827893
   PubMedGoogle Scholar
• Pichler WJ, Yerly D. Drug hypersensitivity: we need to do more. J Allergy Clin Immunol. 2018, Jan;141(1):89–91. doi: 10.1016/j.jaci.2017.11.002
   PubMed Web of Science ®Google Scholar
• Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis. 2006 Jul 1;43(1):99–102. doi: 10.1086/504874
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008 Feb 7;358(6):568–579. doi: 10.1056/NEJMoa0706135
   PubMed Web of Science ®Google Scholar
• Ostrov DA, Grant BJ, Pompeu YA, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):9959–9964. doi: 10.1073/pnas.1207934109
   PubMed Web of Science ®Google Scholar
• Norcross MA, Luo S, Lu L, et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS. 2012 Jul 17;26(11):F21–9. doi: 10.1097/QAD.0b013e328355fe8f
   PubMed Web of Science ®Google Scholar
• Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature. 2012 Jun 28;486(7404):554–558. doi: 10.1038/nature11147
   PubMed Web of Science ®Google Scholar
• Schroder K, Tschopp J. The inflammasomes. Cell. 2010 Mar 19;140(6):821–832. doi: 10.1016/j.cell.2010.01.040
   PubMed Web of Science ®Google Scholar
• Man SM, Kanneganti TD. Regulation of inflammasome activation. Immunol Rev. 2015, May;265(1):6–21. doi: 10.1111/imr.12296
   PubMed Web of Science ®Google Scholar
• Fink SL, Cookson BT. Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol. 2006, Nov;8(11):1812–1825. doi: 10.1111/j.1462-5822.2006.00751.x
   PubMed Web of Science ®Google Scholar
• Franchi L, Warner N, Viani K, et al. Function of nod-like receptors in microbial recognition and host defense. Immunol Rev. 2009, Jan;227(1):106–128. doi: 10.1111/j.1600-065X.2008.00734.x
   PubMedGoogle Scholar
• Yeon SH, Yang G, Lee HE, et al. Oxidized phosphatidylcholine induces the activation of NLRP3 inflammasome in macrophages. J Leukocyte Biol. 2017, Jan;101(1):205–215. doi: 10.1189/jlb.3VMA1215-579RR
   PubMed Web of Science ®Google Scholar
• Kumar H, Kumagai Y, Tsuchida T, et al. Involvement of the NLRP3 inflammasome in innate and humoral adaptive immune responses to fungal beta-glucan. J Immunol. 2009 Dec 15;183(12):8061–7. doi: 10.4049/jimmunol.0902477
   PubMed Web of Science ®Google Scholar
• Park S, Juliana C, Hong S, et al. The mitochondrial antiviral protein MAVS associates with NLRP3 and regulates its inflammasome activity. J Immunol. 2013 Oct 15;191(8):4358–4366. doi: 10.4049/jimmunol.1301170
   PubMed Web of Science ®Google Scholar
• Watanabe H, Gaide O, Petrilli V, et al. Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol. 2007, Aug;127(8):1956–63. doi: 10.1038/sj.jid.5700819
   PubMed Web of Science ®Google Scholar
• Sutterwala FS, Ogura Y, Szczepanik M, et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity. 2006, Mar;24(3):317–327. doi: 10.1016/j.immuni.2006.02.004
   PubMed Web of Science ®Google Scholar
• Imaeda AB, Watanabe A, Sohail MA, et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest. 2009, Feb;119(2):305–314. doi: 10.1172/JCI35958
   PubMed Web of Science ®Google Scholar
• Kato R, Ijiri Y, Hayashi HT. Amiodarone, unlike Dronedarone, activates inflammasomes via its reactive metabolites: implications for amiodarone adverse reactions. Chem Res Toxicol. 2021 Aug 16;34(8):1860–1865. doi: 10.1021/acs.chemrestox.1c00127
   PubMed Web of Science ®Google Scholar
• Sernoskie SC, Lobach AR, Kato R, et al. Clozapine Induces an Acute Proinflammatory Response That Is Attenuated by Inhibition of Inflammasome Signaling: Implications for Idiosyncratic Drug-Induced Agranulocytosis. Toxicol Sci. 2022 Feb 28;186(1):70–82. doi: 10.1093/toxsci/kfab154
   PubMed Web of Science ®Google Scholar
• Kato R, Ijiri Y, Hayashi T, et al. Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673–680.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Sato K, Niioka T, et al. Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib. Med Oncol. 2016, Jun;33(6):57. doi: 10.1007/s12032-016-0773-5
   PubMed Web of Science ®Google Scholar
• Li X, Kamenecka TM, Cameron MD. Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. Chem Res Toxicol. 2009, Oct;22(10):1736–1742. doi: 10.1021/tx900256y
   PubMed Web of Science ®Google Scholar
• Yan M, Li W, Li WB, et al. Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice. Drug Metab Rev. 2023, Feb;55(1–2):94–106. doi: 10.1080/03602532.2022.2149775
   PubMed Web of Science ®Google Scholar
• Puig M, Norcross MA. Transgenic murine models for the study of drug hypersensitivity reactions linked to HLA-I molecules. Curr Opin Allergy Clin Immunol. 2023 Aug 1;23(4):279–286. doi: 10.1097/ACI.0000000000000913
   PubMed Web of Science ®Google Scholar